Medical Professionals
RPx is a next-generation HSV‑1 – based oncolytic immunotherapy platform. RPx can be injected into most lesions, including both superficial and deep lesions, which may afford the opportunity to target distinct tumor and immune microenvironments, maximize anti-tumor activity and immune stimulation.
Research and Educational Support
* Submission of a request does not indicate that Replimune has agreed to fund your request. Decisions regarding funding are made only after the company has received and reviewed your complete request. You will be notified of the decision via an email sent to the address you provide upon registration. All decisions are final and in the complete discretion of Replimune.
Expanded access
Replimune has established an individual patient expanded access (IPEA) process in accordance with FDA recommendations and standard guidance for companies/sponsors to address unmet needs in patients that have exhausted approved therapies and do not qualify for an existing clinical trial. The IPEA process allows us to consider requests for individual patient access to our investigational immunotherapy, RP1, outside of Replimune sponsored clinical trials, e.g., in indications or settings where RP1 has shown initial signs of activity yet the patient does not qualify for one of our ongoing clinical trials, or where a strong scientific rationale exists.